Enzolytics, Inc. (OTCMKTS:ENZC) Sees Significant Decrease in Short Interest

Enzolytics, Inc. (OTCMKTS:ENZC) saw a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 499,900 shares, a decline of 24.5% from the February 13th total of 662,300 shares. Based on an average trading volume of 10,339,000 shares, the days-to-cover ratio is presently 0.0 days.

Enzolytics Price Performance

Enzolytics stock opened at $0.00 on Tuesday. Enzolytics has a 1 year low of $0.00 and a 1 year high of $0.01.

Enzolytics Company Profile

Enzolytics Inc, a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy.